Antisense Oligonucleotides Market
Antisense Oligonucleotides are the Promising Elixir for Several Disorders. Get to Know the Key Trends
Antisense Oligonucleotides Market by Drug, Indication, Application & Region - Forecast 2022 - 2032
Antisense Oligonucleotides Market Outlook (2022-2032)
[306 Pages Report] The global antisense oligonucleotides market is projected to amass revenue of around US$ 5,659.2 million by 2032, up from US$ 1,921.6 million in 2022 moving forward with a CAGR of 10.3% during the forecast period.
The antisense oligonucleotides adoption trends are significantly swayed by the fact that they offer promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics, propelling the market growth. They can target a particular malfunctioning gene, interfere with RNA function at cellular level, and can also be silenced or modulated and the same is catching the attention of market players.
The rising demand for antisense oligonucleotides can be attributed to the aid provided by it in modifying immune system that facilitates treatment of a wide range of autoimmune disorders – that cannot be treated with available drugs.
|
Report Attribute |
Details |
|
Antisense Oligonucleotides Market Value (2022) |
US$ 1,921.6 million |
|
Antisense Oligonucleotides Market Anticipated Forecast Value (2032) |
US$ 5,659.2 million |
|
Antisense Oligonucleotides Market Projected Growth Rate (2022-2032) |
10.3% |
It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.
Moreover, the market enhanced by the minimal side effects of antisense oligonucleotides, which can be controlled with ease as compared to other class of drugs.
The antisense oligonucleotides market has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 – which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).
However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.
However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes for infant mortality with no approved treatments.
Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the antisense oligonucleotides market outlook is positively influenced by the leadings players in the market and the amount of research and development investments.
Let us know your requirement to get
100% FREE customization
What Factors are Shaping the Antisense Oligonucleotides Market?
Strong pipeline of antisense oligonucleotides and increased focused on large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides market size.
Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level is further contributing to the growth of the global antisense oligonucleotides market.
However, the global antisense oligonucleotides market is grappling with numerous challenges related to diversity of oligonucleotides, delivery, and regulatory complexity.
Despite several advancements at clinical levels, the delivering of active oligonucleotide to the actual site within target cells is still one of the major challenges hindering the growth of the global antisense oligonucleotides market. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the antisense oligonucleotides market statistics.
Why is North America Expected to Dominate the Antisense Oligonucleotides Market?
North America clearly dominates the global antisense oligonucleotides market due to a strong product pipeline and increasing number of FDA approvals in the region, contributing to the region’s antisense oligonucleotides market share of 56% in 2022.
For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the United States in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Growth Prospects for the Europe Antisense Oligonucleotides Market?
In 2022, the Europe antisense oligonucleotides market is likely to capture a share of 10.0%. In order to improve their product portfolio for antisense oligonucleotides, major players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the antisense oligonucleotides market growth in Europe.
For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company Astra Zeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market grow to some level..
How is the Start-Up Ecosystem in the Antisense Oligonucleotides Market?
While there are many organizations working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are emerging as well which are shaping the market trends.
Examples:
- RNA-targeting biopharmaceuticals are being created by the US-based start-up Arrakis Therapeutics.
The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.
These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.
- Antisense RNA therapies are created by the Spanish start-up ARTHEx Biotech for hereditary illnesses.
The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients
A unified Market Research Subscription Platform, built for today's disparate research needs.
How Strong is the Competition in the Antisense Oligonucleotides Market?
The market for antisense oligonucleotides is fairly consolidated, with a few number of competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.
A couple of recent developments in the antisense oligonucleotides market are:
- AmpTec, a renowned German company that specialises in mRNA contract development and manufacture, was purchased by MilliporeSigma (US) (CDMO).
The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.
- oPools- oligo pools, a collection of 350-nucleotide-long, high-quality DNA oligonucleotides, was introduced by Integrated DNA Technology (US).
Key player:
- Ionis Pharmaceuticals, Inc.
- Sarepta Therapeutics
- Biogen
- Alnylam Pharmaceuticals, Inc.
- Antisense Therapeutics Limited
- Isarna Therapeutics GmbH
- Arrowhead Pharmaceuticals, Inc.
- Alantic Pharmaceuticals, Inc.
- Enzon Pharmaceuticals, Inc.
- Bio-Path Holdings, Inc.
- Gene Signal International SA
- GlaxoSmithKline plc
- Geron Corporation
- Gradalis
- ICO Therapeutics
- Aptose Biosciences
- Marina Biotech
- miRagen Therapeutics, Inc.
- Synlogic, Inc.
- OncoGenex Pharmaceuticals Inc.
- Pharmaxis Ltd, Regulus Therapeutics Inc.
- Rexahn Pharmaceuticals, Inc.
- RXi Pharmaceuticals
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 10.3% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
Key Segments Profiled in the Antisense Oligonucleotides Market Survey
By Drug:
- Approved Drugs
- Pegaptanib
- Mipomersen
- Eteplirsen
- Pipeline Analysis
By Indication:
- Ocular Diseases
- Cancer
- Diabetes
- Amyotrophic Lateral Sclerosis (ALS)
- Duchenne Muscular Dystrophy
- Spinal Muscular Atrophy
- Others
By Application:
- Basic Research
- Genomics
- Target Validation
- Drug Discovery
By Region:
- North America
- Latin America
- Asia Pacific
- The Middle East and Africa
- Europe
Frequently Asked Questions
The global antisense oligonucleotides market is likely to advance at 10.3% CAGR (2022-2032).
North America is projected to lead the antisense oligonucleotides market with a share of 56% in 2022.
Antisense oligonucleotides market is anticipated to account for US$ 5,659.2 million by 2032.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Drug
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug, 2022-2032
5.3.1. Approved Drugs
5.3.1.1. Pegaptanib
5.3.1.2. Mipomersen
5.3.1.3. Eteplirsen
5.3.2. Pipeline Analysis
5.4. Y-o-Y Growth Trend Analysis By Drug, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug, 2022-2032
6. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032
6.3.1. Ocular Diseases
6.3.2. Cancer
6.3.3. Diabetes
6.3.4. Amyotrophic Lateral Sclerosis (ALS)
6.3.5. Duchenne Muscular Dystrophy
6.3.6. Spinal Muscular Atrophy
6.3.7. Others
6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
7. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By End Usr
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End Usr , 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End Usr , 2022-2032
7.3.1. Basic Research
7.3.2. Genomics
7.3.3. Target Validation
7.3.4. Drug Discover
7.4. Y-o-Y Growth Trend Analysis By End Usr , 2017-2021
7.5. Absolute $ Opportunity Analysis By End Usr , 2022-2032
8. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Drug
9.2.3. By Indication
9.2.4. By End Usr
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug
9.3.3. By Indication
9.3.4. By End Usr
9.4. Key Takeaways
10. Latin America Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug
10.2.3. By Indication
10.2.4. By End Usr
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug
10.3.3. By Indication
10.3.4. By End Usr
10.4. Key Takeaways
11. Europe Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug
11.2.3. By Indication
11.2.4. By End Usr
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug
11.3.3. By Indication
11.3.4. By End Usr
11.4. Key Takeaways
12. Asia Pacific Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. India
12.2.1.5. Malaysia
12.2.1.6. Singapore
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of APAC
12.2.2. By Drug
12.2.3. By Indication
12.2.4. By End Usr
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug
12.3.3. By Indication
12.3.4. By End Usr
12.4. Key Takeaways
13. MEA Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug
13.2.3. By Indication
13.2.4. By End Usr
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug
13.3.3. By Indication
13.3.4. By End Usr
13.4. Key Takeaways
14. Key Countries Antisense Oligonucleotides Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Drug
14.1.2.2. By Indication
14.1.2.3. By End Usr
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Drug
14.2.2.2. By Indication
14.2.2.3. By End Usr
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Drug
14.3.2.2. By Indication
14.3.2.3. By End Usr
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Drug
14.4.2.2. By Indication
14.4.2.3. By End Usr
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Drug
14.5.2.2. By Indication
14.5.2.3. By End Usr
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Drug
14.6.2.2. By Indication
14.6.2.3. By End Usr
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Drug
14.7.2.2. By Indication
14.7.2.3. By End Usr
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Drug
14.8.2.2. By Indication
14.8.2.3. By End Usr
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Drug
14.9.2.2. By Indication
14.9.2.3. By End Usr
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Drug
14.10.2.2. By Indication
14.10.2.3. By End Usr
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Drug
14.11.2.2. By Indication
14.11.2.3. By End Usr
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Drug
14.12.2.2. By Indication
14.12.2.3. By End Usr
14.13. Malaysia
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Drug
14.13.2.2. By Indication
14.13.2.3. By End Usr
14.14. Singapore
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Drug
14.14.2.2. By Indication
14.14.2.3. By End Usr
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Drug
14.15.2.2. By Indication
14.15.2.3. By End Usr
14.16. New Zealand
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Drug
14.16.2.2. By Indication
14.16.2.3. By End Usr
14.17. GCC Countries
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Drug
14.17.2.2. By Indication
14.17.2.3. By End Usr
14.18. South Africa
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Drug
14.18.2.2. By Indication
14.18.2.3. By End Usr
14.19. Israel
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Drug
14.19.2.2. By Indication
14.19.2.3. By End Usr
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug
15.3.3. By Indication
15.3.4. By End Usr
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Ionis Pharmaceuticals, Inc
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Sarepta Therapeutics
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Biogen
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Alnylam Pharmaceuticals, Inc
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Antisense Therapeutics Limited
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Isarna Therapeutics GmbH
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Arrowhead Pharmaceuticals, Inc
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Atlantic Pharmaceuticals, Inc
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Enzon Pharmaceuticals, Inc
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Bio-Path Holdings, Inc
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. Gene Signal International SA
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. GlaxoSmithKline plc
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
16.1.13. Geron Corporation
16.1.13.1. Overview
16.1.13.2. Product Portfolio
16.1.13.3. Profitability by Market Segments
16.1.13.4. Sales Footprint
16.1.13.5. Strategy Overview
16.1.13.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032
Table 3: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 4: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032
Table 5: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032
Table 7: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 8: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032
Table 9: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032
Table 11: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 12: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032
Table 13: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032
Table 15: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 16: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032
Table 17: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032
Table 19: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 20: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032
Table 21: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032
Table 23: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 24: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032
Figure 2: Global Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032
Figure 3: Global Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032
Figure 4: Global Antisense Oligonucleotides Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032
Figure 9: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032
Figure 10: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032
Figure 11: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 12: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 13: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 14: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032
Figure 15: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032
Figure 16: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032
Figure 17: Global Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032
Figure 18: Global Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032
Figure 19: Global Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032
Figure 20: Global Antisense Oligonucleotides Market Attractiveness by Region, 2022-2032
Figure 21: North America Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032
Figure 22: North America Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032
Figure 23: North America Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032
Figure 24: North America Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032
Figure 29: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032
Figure 30: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032
Figure 31: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 32: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 33: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 34: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032
Figure 35: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032
Figure 36: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032
Figure 37: North America Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032
Figure 38: North America Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032
Figure 39: North America Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032
Figure 40: North America Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032
Figure 42: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032
Figure 43: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032
Figure 44: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032
Figure 49: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032
Figure 50: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032
Figure 51: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 52: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 53: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 54: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032
Figure 55: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032
Figure 56: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032
Figure 57: Latin America Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032
Figure 58: Latin America Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032
Figure 59: Latin America Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032
Figure 60: Latin America Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032
Figure 61: Europe Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032
Figure 62: Europe Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032
Figure 63: Europe Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032
Figure 64: Europe Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032
Figure 69: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032
Figure 70: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032
Figure 71: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 72: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 73: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 74: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032
Figure 75: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032
Figure 76: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032
Figure 77: Europe Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032
Figure 78: Europe Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032
Figure 79: Europe Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032
Figure 80: Europe Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032
Figure 82: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032
Figure 83: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032
Figure 84: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032
Figure 89: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032
Figure 90: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032
Figure 91: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 92: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 93: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 94: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032
Figure 95: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032
Figure 96: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032
Figure 97: Asia Pacific Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032
Figure 98: Asia Pacific Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032
Figure 99: Asia Pacific Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032
Figure 100: Asia Pacific Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032
Figure 101: MEA Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032
Figure 102: MEA Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032
Figure 103: MEA Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032
Figure 104: MEA Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032
Figure 109: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032
Figure 110: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032
Figure 111: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 112: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 113: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 114: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032
Figure 115: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032
Figure 116: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032
Figure 117: MEA Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032
Figure 118: MEA Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032
Figure 119: MEA Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032
Figure 120: MEA Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
